Efficacy of Upfront Docetaxel With Androgen Deprivation Therapy for Castration-Sensitive Metastatic Prostate Cancer Among Minority Patients.
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Therapeutics"
DOI: 10.1097/mjt.0000000000001085
Abstract: BACKGROUND Upfront docetaxel (UD) with androgen deprivation therapy (ADT) has been demonstrated to improve survival outcomes in metastatic castration-sensitive prostate cancer (mCSPC). However, existing studies have included predominantly Caucasian patients. STUDY QUESTION To compare the… read more here.
Keywords: adt; androgen deprivation; deprivation therapy; docetaxel androgen ... See more keywords
Is it the time to shift paradigms in castration naïve prostate cancer (CNPC): A meta-analysis of upfront docetaxel and abiraterone in men with CNPC.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.6_suppl.360
Abstract: 360Background: To systematically review the relevant literature evaluating the therapeutic efficacy of upfront docetaxel (Doc) or abiraterone (Abi) plus androgen deprivation therapy (ADT) on oncological outcome in patients with CNPC. An attempt to identify subgroups… read more here.
Keywords: cnpc; upfront docetaxel; abiraterone; meta analysis ... See more keywords